Cytokinetics Inc (CYTK) Peer Comparison

$65.98

$0.07 (0.11%)

As on 01-Oct-2026 14:37EDT

Market cap

$8,989 Mln

Revenue (TTM)

$71 Mln

P/E Ratio

--

P/B Ratio

60.3

Div. Yield

0 %

Edit

	Cytokinetics Inc (CYTK)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Halozyme Therapeutics (HALO)
Market cap ($ Mln)	8,989	17,274	14,841	14,411	12,927
Revenue ($ Mln)	71	2,782	1,054	2,436	1,664
Net Profit ($ Mln)	-894.00	491.50	755.85	860.62	413.60
Net Margin (%)	-1,259.87	17.67	71.69	35.33	24.86
RoE (%)	--	110.09	--	42.98	430.03
Price to Earnings	--	36.40	17.63	18.29	33.40
Price-To-Book	60.31	39.70	8.91	7.82	88.91

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement ($ Mln)

	Cytokinetics Inc (CYTK)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Halozyme Therapeutics (HALO)
Operating Revenue	70.96	2,782.29	1,054.37	2,435.92	1,663.74
Cost of Revenue	10.66	1,982.07	103.47	85.67	363.07
Gross Profit	77.91	760.62	588.53	2,236.43	1,091.18
Operating Expenses	764.92	216.81	841.45	1,378.74	356.18
Operating Profit (EBIT)	-704.62	583.40	109.45	971.51	944.49
Other Income	0.00	0.00	0.00	0.00	0.00
Profit before Tax	-894.00	598.92	101.11	1,035.47	583.34
Provision for Tax	0.00	107.42	-654.74	174.84	169.74
Profit after Tax (Net Income)	-894.00	491.50	755.85	860.62	413.60
Minority Interest	0.00	0.00	0.00	0.00	0.00
Consolidated Profit	0.00	0.00	0.00	0.00	0.00

Liabilities ($ Mln)

	Cytokinetics Inc (CYTK)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Halozyme Therapeutics (HALO)
Shareholder's Funds	-173.49	433.86	1,435.90	1,843.76	143.54
Minority Interest	0.00	0.00	0.00	0.00	0.00
Non-Current Liabilities	1,916.61	187.89	384.48	288.55	2,089.43
Current Liabilities	181.43	1,435.43	464.70	361.93	344.44
Total Liabilities	1,424.54	1,975.47	1,302.02	2,844.42	2,525.32

Assets ($ Mln)

	Cytokinetics Inc (CYTK)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Halozyme Therapeutics (HALO)
Non-Current Assets	716.06	1,006.90	895.24	1,243.41	1,644.38
Current Assets	1,208.49	1,050.29	1,389.84	1,250.82	933.02
Total Assets	1,424.54	1,975.47	1,302.02	2,844.42	2,525.32
Total Debt*	1,270.56	120.10	449.89	165.93	2,146.65
Net Current Assets	1,027.06	-385.14	925.52	888.90	588.59

Cashflow ($ Mln)

	Cytokinetics Inc (CYTK)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Halozyme Therapeutics (HALO)
Cash From Operating Activities	-510.01	713.22	51.77	884.27	651.56
Cash Flow from Investing Activities	16.67	-31.14	-8.15	350.44	-545.81
Cash from Financing Activities	524.46	-860.39	34.89	-969.59	-85.17
Net Cash Inflow / Outflow	--	--	--	--	--

Ratios

Profitability Ratios

	Cytokinetics Inc (CYTK)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Halozyme Therapeutics (HALO)
ROCE (%)	-122.85	53.56	-30.01	32.82	15.61
ROE (%)	197.47	110.09	163.18	42.98	430.03
ROA (%)	-51.64	15.64	31.68	29.32	16.19
EBIT Margin (%)	-1,175.80	21.13	5.73	31.04	36.28
Net Margin (%)	-1,259.87	17.67	71.69	35.33	24.86
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

Growth Ratios

	Cytokinetics Inc (CYTK)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Halozyme Therapeutics (HALO)
Revenue Growth (%)	-17.24	24.67	114.85	9.23	41.15
EBIT Growth (%)	-62.26	18.70	136.39	-3.99	-14.99
Net Profit Growth (%)	-47.45	17.50	378.76	42.89	-25.78
EPS Growth (%)	-41.03	26.84	353.27	50.42	-23.48
Book Value Growth (%)	57.45	164.02	816.12	-0.70	-55.81

Valuation Ratios

	Cytokinetics Inc (CYTK)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Halozyme Therapeutics (HALO)
Price / Earnings	-9.91	36.06	-59.76	15.79	24.99
Price / Book Value	-11.79	35.44	-80.42	5.72	162.23
Dividend Yield (%)	--	--	--	--	--
EV/EBITDA	-10.55	28.08	-121.54	12.44	17.31
Market Cap ($ Cr)	--	--	--	--	--

Solvency Ratios

	Cytokinetics Inc (CYTK)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Halozyme Therapeutics (HALO)
Debt to Equity	-6.45	0.00	0.27	0.00	13.50
Short term debt to equity ratio	-0.28	0.00	0.05	0.00	1.46
Current Ratio	6.66	0.73	2.99	3.46	2.71
Quick Ratio	6.66	0.73	2.32	3.38	2.31
Interest Coverage	-6.16	--	1.62	--	29.73

Operating Efficiency Ratios

	Cytokinetics Inc (CYTK)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Halozyme Therapeutics (HALO)
Debtors to sales (%)	34.43	15.88	21.25	13.74	27.40
Asset Turnover	0.04	0.89	0.44	0.83	0.65
Receivable days	71.39	50.42	85.52	43.48	98.04
Inventory Days	--	--	1,056.70	96.17	190.34
Payable days	770.29	6.26	331.01	147.97	18.62
Cash Conversion Cycle	--	--	811.21	-8.32	269.75

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Annual
Quarterly